Revenue: $559 million, up 8% year-over-year and 10% on a constant currency basis. Adjusted EBITDA Margin: Increased by 160 basis points to 17.7%. Recon Business Growth: 13% growth with double-digit growth globally in hip, knee, and extremities. P&R Business Growth: 8% growth, mid-single digit when adjusted for selling days. Adjusted Gross Margin: 61.7%, an increase of 300 basis points year-over-year. Adjusted Earnings Per Share: $0.81, an increase of 62% versus prior year. Interest Expense: $9 million, down from $20 million in 2024. Effective Tax Rate: 23%, approximately 70 basis points higher than last year. 2025 Revenue Guidance: Increased by $30 million to $2.22 billion to $2.25 billion. 2025 Adjusted EBITDA Guidance: Lowered to $385 million to $395 million. 2025 Adjusted EPS Guidance: Updated to $2.95 to $3.10, down $0.15 from prior guidance. Tariff Exposure: $40 million expected in 2025, with plans to mitigate to $20 million.

Warning! GuruFocus has detected 3 Warning Signs with ENOV.

Release Date: May 08, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Enovis Corp (NYSE:ENOV) reported an 8% growth in sales for Q1 2025, with a 10% increase on a constant currency basis. The company achieved a 13% growth in its Recon business, with double-digit growth in both hip and knee segments. Adjusted EBITDA margins improved by 160 basis points, driven by favorable segment and product mix. The company launched several new products, including the augmented reverse glenoid system in shoulders and the nebula stem in hips, contributing to growth. Enovis Corp (NYSE:ENOV) maintained a strong international performance, with a 14% growth outside the US, showcasing the strength of its global position.

Negative Points

The company faces a $40 million tariff exposure for 2025, with plans to mitigate it to $20 million, impacting profitability. Enovis Corp (NYSE:ENOV) lowered its adjusted EBITDA guidance by $20 million due to expected tariff impacts in the second half of 2025. The effective tax rate increased by 70 basis points compared to the previous year. Interest expense for the quarter was $9 million, although reduced from $20 million in 2024. The company anticipates a slight downward trend in pricing within the Recon market, which could affect future margins.

Q & A Highlights

Q: What actions are being taken to mitigate tariff impacts, and which are most significant for long-term supply availability? A: Matthew Trerotola, CEO, stated that the most significant action is moving product sourcing out of China, where most tariff exposure originates. This involves shifting production to other countries, which will reduce the need for other mitigation strategies like commercial actions.

Story Continues

Q: Can you provide an update on the ARG launch and general market trends? A: Matthew Trerotola, CEO, reported that the ARG launch is progressing well, contributing to strong extremities growth. The market had a healthy start to the year, with strong performance in January and February, and a solid outlook for April.

Q: How did the US performance in bracing and Recon compare to expectations? A: Matthew Trerotola, CEO, noted that US bracing performed strongly, driven by clinic conversions and new product introductions. Recon's performance was in line with expectations, with new product launches and enabling technologies expected to sustain growth.

Q: What is the outlook for gross margins, and are they sustainable? A: Ben Berry, CFO, explained that positive business mix and new product contributions are driving gross margin improvements. Despite tariff headwinds expected in the second half, underlying performance is strong, and margins are expected to remain positive.

Q: How is the ARVIS shoulder launch progressing, and what are the plans for broader rollout? A: Matthew Trerotola, CEO, stated that the ARVIS shoulder launch is going well, with positive feedback from surgeons. The product is generating significant interest and energy around the shoulder business, with plans for broader rollout and international launch this year.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments